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Genetically inactivated, Gram-negative bacteria that express malaria vaccine candidates
represent a promising novel self-adjuvanting vaccine approach. Antigens expressed on
particulate bacterial carriers not only target directly to antigen-presenting cells but also
provide a strong danger signal thus circumventing the requirement for potent extraneous
adjuvants. E. coli expressing malarial antigens resulted in the induction of eitherTh1 orTh2
biased responses that were dependent on both antigen and sub-cellular localization. Some
of these constructs induced higher quality humoral responses compared to recombinant
protein and most importantly they were able to induce sterile protection against sporo-
zoite challenge in a murine model of malaria. In light of these encouraging results, two
major Plasmodium falciparum pre-erythrocytic malaria vaccine targets, the Cell-Traversal
protein for Ookinetes and Sporozoites (CelTOS) fused to the Maltose-binding protein in the
periplasmic space and the Circumsporozoite Protein (CSP) fused to the Outer membrane
(OM) protein A in the OM were expressed in a clinically relevant, attenuated Shigella strain
(Shigella flexneri 2a). This type of live-attenuated vector has previously undergone clinical
investigations as a vaccine against shigellosis. Using this novel delivery platform for malaria,
we find that vaccination with the whole-organism represents an effective vaccination alter-
native that induces protective efficacy against sporozoite challenge. Shigella GeMI-Vax
expressing malaria targets warrant further evaluation to determine their full potential as
a dual disease, multivalent, self-adjuvanting vaccine system, against both shigellosis, and
malaria.
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INTRODUCTION
While traditional whole-cell, killed, or live-attenuated microorg
anism-based vaccines have been the most effective for disease
prevention, a large number of subunit vaccines are currently in
development and are being evaluated for their ability to elicit
protective immune responses. These approaches include DNA
vaccines, recombinant protein (with adjuvant or as conjugates),
viral vectors, and bacteria expressing full-length or immunolog-
ically crucial antigens (1–11). Vaccine development for the three
major human diseases, namely HIV, tuberculosis, and malaria, has
been primarily impeded by host immune evasion mechanisms
employed by pathogens, the poor immunogenicity of protective
antigens and/or the inability to generate effective whole-organism
vaccines. Poor immunogenicity can often be overcome by admin-
istering the vaccine with potent adjuvants (12, 13). However,
the limited repertoire and availability of human-use adjuvants
is hampering the clinical vaccine development pipeline (14).
Using recombinant viruses or bacteria as vectors could overcome
some of these limitations. Vaccination with live-attenuated organ-
isms mimic the immune stimulation of natural infections and
offer induction of a more natural and robust immune response.
Although some concerns over their safety have prevented their uni-
versal acceptance and licensure; recent advances toward increased
safety through detoxification and unique delivery routes may quell
some of these concerns. Using bacteria as recombinant vectors to
mount an immune response against xenogeneic transgenes has
several advantages: (1) pathogen-associated molecular patterns
(PAMPs) on the bacteria are recognized by specialized pattern
recognition receptors (PRRs) of the host and lead to the activation
of strong innate immune responses (15). This is the crucial first
step in initiating an antigen-specific adaptive immune response.
Depending on the type of PAMPs, distinctive types of adaptive
immune responses are induced. (2) Complement factors MBL,
C1q, and C3b also recognize PAMPs which results in proteolytic
activation of the complement cascade. Binding with complement
mediates the targeting of the bacteria to the complement receptors
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(CR) on antigen-presenting cells (APC) (16) therefore improving
the antigen presentation of xenogeneic antigens. (3) In individ-
uals with pre-existing immunity to the bacterium, cross-linking
between antigen receptor and CR results in strong activation of
the respective B cells (17, 18) thus improving humoral immune
responses. (4) Opsonized pathogens targeted to CR on follic-
ular dendritic cells ensure long-lasting immunity (19–21). (5)
Finally, using bacteria of clinical relevance as vectors for deliv-
ery of xenogeneic pathogen-derived antigens holds the poten-
tial for their application as dual-use vaccines. Currently, several
virulence-attenuated bacteria are used as vaccines and are either
commercially available or in clinical development, i.e., Salmonella
enterica serovar Typhi Ty21a (22, 23),Vibrio cholera CVD 103-HgR
(24, 25), Mycobacterium bovis BCG (26–28), Shigella dysenteriae
Type 1, Shigella flexneri 2a, and Shigella sonnei (29–33).
These advantages warrant further evaluation of recombinant
bacteria as vectors for delivering heterologous target antigens
either by co-expression, adsorption, or encapsulation (28, 34–
37). Traditionally, microorganisms have been inactivated or killed
using methods with strong denaturing conditions involving heat
or chemical treatments such as formaldehyde or formalin. This
process is meant to ensure the safety of the formulation but
the harsh treatment can negatively affect the structure of the
pathogen’s proteins and thus antigenicity of key protective anti-
gens (38, 39). Molecular methods to sustain surface antigen func-
tionality and integrity that circumvent these denaturing condi-
tions include the controlled expression of PhiX174 gene E leading
to the concept of Bacterial Ghosts (BGs) as a vaccine delivery plat-
form (40, 41). A new approach to inactive bacteria not previously
described uses genetic means to express inhibitors of key meta-
bolic processes that disrupt cellular functions without significantly
altering bacterial cell structure integrity. In the current study,
we utilize this Gene-Mediated-Inactivation Vaccine (GeMI-Vax)
process to generate inactivated Gram-negative bacteria carrying
heterologous protein antigens. In GeMI-Vax production, a Gram-
negative pathogen is transformed with plasmids containing a gene
for an antigen of interest and the GeMI-Vax inactivation gene,
ColE3, which encodes a colicin that degrades mRNA. GeMI-Vax
bacteria serve as the antigen delivery system in the context of
whole bacterial cells that are rendered non-replicating and non-
viable through this type of genetic manipulation. Moreover, since
these bacteria are not chemically modified, conformational epi-
topes on the recombinant antigens, and the bacterial derived
PAMPs (such as lipopolysaccharide, lipoproteins, flagellin, and
DNA) are unchanged allowing for the induction of potent immune
responses. The advantage of using GeMI-Vax bacteria as delivery
platform compared to traditional adjuvants is that a wide range of
PAMPs can trigger distinct PRRs, both surface bound (e.g., TLR-4)
and intracellular (e.g., TLR-9) thus resulting in the engagement of
multiple signaling pathways.
Malaria caused by Plasmodium falciparum results in serious ill-
ness and often leads to death if left untreated. The development
of an efficacious vaccine to prevent this global disease is of utmost
importance. There is an urgent need to develop a highly effica-
cious, low cost, self-adjuvanting, pre-erythrocytic stage malaria
vaccine from P. falciparum target antigens (sporozoite and liver
stages) to protect populations in malaria endemic regions. In
initial studies, Escherichia coli GeMI-Vax were co-transformed
with plasmids expressing the malaria target antigen and the bac-
terial host inactivation gene product. The malaria targets used
in the E. coli experiments was the rodent malaria Plasmodium
berghei Circumsporozoite Protein (PbCSP) and the Cell-traversal
protein of ookinetes and sporozoites (PbCelTOS). Three sub-
cellular localizations of the target were evaluated; expression in
the cytosol (Cyto), the periplasmic space (PPS), and the outer
membrane (OM) of the bacterial carrier. Localization to the PPS
and OM was accomplished through genetic fusions between the
Maltose-Binding Protein (MBP) and the Outer Membrane Protein
A (OmpA), forming chimeric proteins with the malaria targets.
Culture conditions were optimized to maximize antigen expres-
sion, effective bacterial inactivation, and the isolation of whole,
intact GeMI-Vax cells. Since no harsh physical or chemical agents
are employed, proteins, and other immune-stimulating compo-
nents of GeMI-Vax cells are intact and recognized by the immune
system in the same manner as their live pathogenic counterpart.
Thus they elicit a robust immune response without the need
for additional adjuvants. GeMI-Vax cells were evaluated for their
ability to induce protection against malaria challenge in murine
challenge models, and both the humoral and cellular immune
responses were evaluated.
Evidence of immunological potency and protection from stud-
ies performed using E. coli GeMI-Vax supported translation to the
clinically more relevant whole-cell Shigella flexneri as the delivery
platform. The GeMI-Vax platform was used to inactivate engi-
neered Shigella flexneri 2a (15G strain) expressing P. falciparum
CelTOS (PfCelTOS) in the PPS or P. falciparum CSP (PfCSP)
on the OM. Similar to E. coli GeMI-Vax, the Shigella GeMI-Vax
cells have none of the disadvantages of chemical killing or regu-
latory hurdles associated with live vaccines. The live-attenuated S.
flexneri used in this study were previously shown to be safe and
protective in an animal model when administered intranasally
(42). Both applications of GeMI-Vax, E. coli, and S. flexneri 2a
(15G strain), expressing malaria targets on the surface of bac-
teria elicited antigen-specific antibodies and IFN-γ producing T
cells when expressed on the OMs. Malaria antigen localized to
intracellular spaces, i.e., periplasmic and cytosol, skewed toward
cellular responses with no significant levels of antibodies detected.
Thus the protective efficacy of the different constructs supports
GeMI-Vax as a vaccine vector system for delivery of target anti-
gens. Additionally, expressing target antigens at different sites on
bacteria influences the type of immune responses induced and
allows for investigations into antigen-specific immune correlates
of protection.
MATERIALS AND METHODS
PbCSP IN THE CYTOSOL FOR E. COLI EXPRESSION
The Plasmodium berghei (Pb) CSP gene coding sequence was
obtained from the plasmid pET(K-) PbCSP-tr. The gene insert
was synthesized by Retrogen Inc. (San Diego, CA, USA) using
a WRAIR proprietary codon harmonized nucleotide sequence for
optimal expression in E. coli (43). The PbCSP nucleotide sequence
was truncated in the total number of repeat motifs for cloning pur-
poses. The gene product was 572 bp long and contained a His tag
at the 5′end. The final expressed product has a molecular weight
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of 21 kDa, but runs anomalously on gradient Tris-Glycine SDS-
PAGE (Invitrogen, Carlsbad, CA, USA) due to the complex nature
of its structure. The PbCSP-tr DNA from pET(K-)PbCSP-tr was
used for constructing the OM-PbCSP and PPS-PbCSP GeMI-Vax
plasmids as well as for expressing PbCSP in the cytosol of E. coli
(Cyto-PbCSP).
PbCSP IN THE OUTER MEMBRANE FOR E. COLI EXPRESSION
The PbCSP gene from pET(K-)PbCSP-tr was PCR amplified and
cloned into the pVPIHS64K OM vector yielding an E. coli OmpA-
PbCSP fusion protein. After the sequence was confirmed, the
plasmid was used to transform NM522 E. coli cells. Positive
clones were identified by colony PCR using vector specific primers.
Expression was confirmed by induction of bacterial cultures with
1 mM isopropyl-thio-β-galactoside (IPTG) (Roche, Indianapolis,
IN, USA), and analyzed by whole-cell extraction and SDS-PAGE
Western blotting (Invitrogen) using an anti-His6 antibody (Sigma-
Aldrich, St. Louis, MO, USA). Expression was detected at the
expected molecular weight of 60 kDa for the fusion protein. The
PbCelTOS codon harmonized nucleotide sequence was similarly
constructed to be expressed in the OM and the PPS of E. coli (44).
The details for growth, expression, and isolation are identical to
those used for the PbCSP GeMI-Vax constructs.
PbCSP IN THE PERIPLASMIC SPACE FOR E. COLI EXPRESSION
The PbCSP gene coding sequence was obtained from plasmid
pET(K-)PbCSP-tr. The gene was PCR amplified and cloned into
the p2XK MBP vector, yielding an E. coli MBP-PbCSP fusion pro-
tein. After the sequence was confirmed, the plasmid was used to
transform NM522 cells. Positive clones were identified by colony
PCR using vector specific primers. Expression was confirmed by
induction of bacterial cultures with 1 mM IPTG; and analyzed
by whole-cell extraction and SDS-PAGE Western blotting using
an anti-His6 antibody. Expression was detected at the expected
molecular weight of 64 kDa for the fusion protein.
PREPARATION OF E. COLI GeMI-Vax CELLS
E. coli NM522 cells were grown to an OD600 of 0.3 at 30°C in
Hyperbroth (Accurate Chemicals & Scientific Corp., Westbury,
NY, USA) with 2% Glucose Nutrient Mixture™ (Accurate Chem-
icals & Scientific Corp.) media containing 40µg/mL kanamycin
(Sigma-Aldrich) and 20µg/mL gentamicin (Sigma-Aldrich). Key
steps in the GeMI-Vax expression and isolation are outlined in
Table 1. Briefly, E. coli cells were induced with 1 mM IPTG to
express the malaria target antigen for 1 h. Induction of colE3
gene, which encodes a colicin that degrades mRNA, was used for
cell inactivation. The colE3 inactivation gene was cloned behind
the araBAD promoter in a pBAD vector (Invitrogen) (modi-
fied for gentamicin selection) using AflII and NcoI restriction
sites and expression was induced by the addition of 2.5% l-(+)-
arabinose (≥99%, Sigma-Aldrich) for 1.5 h. During cell inacti-
vation, 100µg/mL gentamicin was added to guarantee plasmid
retention. As a final step to ensure 100% cell inactivation, 2 mg/mL
solid streptomycin (Sigma-Aldrich) was added to cultures for 2 h.
Cells were collected by centrifugation at 5,000 rpm for 15 min,
pellets were resuspended in 50 mL sterile water, and the suspen-
sion was stored with 800µg/mL of streptomycin overnight at 4°C.
To determine final cell suspension sterility, 100µL of cells were
plated onto antibiotic-free Luria Broth agar plates and also inocu-
lated into 10 mL liquid culture media with no antibiotics. LB plates
and culture tubes were incubated at 37°C overnight or for 37°C
for 5 days, respectively.
WASHING AND LYOPHILIZATION
For final storage, the cell pellets were washed extensively by sequen-
tial centrifugation and resuspension with four exchanges of sterile
water to remove any residual antibiotics. After the final wash,
cells were aliquoted into cryotubes, snap-frozen in liquid nitro-
gen and kept at −80ºC overnight. Frozen cells were lyophilized
using Labconco-Fast Freeze Flasks (Labconco, Kansas City, MO,
USA) and a Flexi-Dry™ Microprocessor (µP) Control-Corrosion
Resistant Freeze Dryer (FTF Systems, Stone Ridge, NY, USA).
Lyophilization was completed over a two day period at a temper-
ature of −70°C under vacuum (600 mTorr). The final lyophilized
vials were stored at 4°C.
PfCelTOS IN THE PERIPLASMIC SPACE FOR SHIGELLA EXPRESSION
A plasmid containing the Plasmodium falciparum (Pf) CelTOS
gene served as the template for PCR amplification. Briefly, the par-
ent plasmid included a 522 bp DNA fragment of PfCelTOS 3D7
designed by using the codon-harmonization algorithm (43, 45)
and cloned into a modified pET(K−) expression vector (Novagen,
Madison, WI, USA). Oligonucleotides were designed for cloning
the PfCelTOS sequence into the p2xK periplasmic vector yielding
a fusion protein with the MBP. After sequence confirmation, the
plasmid was transformed into S. flexneri 2a (15G strain) (ATCC,
Manassas,VA, USA). Positive clones were identified by colony PCR
using vector specific primers. Expression testing was accomplished
by induction of bacterial cultures with IPTG followed by whole-
cell extraction and SDS-PAGE Western blot using an anti-MBP
antibody (New England BioLabs, Ipswich, MA, USA). Expression
Table 1 | Summary steps for production of GeMI-Vax cells.
Time (min) OD600 Temperature Induction Description
E. coli (°C) Shigella (°C) E. coli Shigella
0 0.3 30 30 IPTG IPTG Induce malaria Ag expression
60 0.6 30 40 Arabinose Temp shift Induction inactivation gene expression
150 30 40 – – Final inactivation with streptomycin
270 30 40 – – Harvest and wash cells
48 h 30 40 – – Lyophilization
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was confirmed at the expected molecular weight of 61 kDa for the
fusion protein.
PfCSP IN THE OUTER MEMBRANE FOR SHIGELLA EXPRESSION
The Plasmodium falciparum (Pf) CSP gene coding sequence was
synthesized by DNA 2.0 (Menlo Park, CA, USA). DNA 2.0 adjusted
the coding sequence for optimized expression in E. coli. The gene
was 807 bp long and a His tag was added to the 5′end. The highly
repetitive central repeat region was retained in its entirety. The
gene was PCR amplified and cloned into the pVPIHS64K OM
vector, yielding an E. coli OmpA-PfCSP fusion protein. After the
sequence was confirmed, the plasmid was used to transform S.
flexneri 2a (15G strain). Positive clones were identified by colony
PCR using vector specific primers. Expression testing was per-
formed by induction of bacterial cultures with IPTG followed by
whole-cell extraction and SDS-PAGE Western blot using an anti-
His6 antibody (Sigma). Expression was detected at the expected
molecular weight of 68.5 kDa.
CONSTRUCTION OF PλColE3 PLASMID
A plasmid synthesized by DNA2.0 (Menlo Park) designated
GV001λVPI was used to engineer the GeMI-Vax inactivation
gene ColE3 behind the lambda promoter. This plasmid contained
the ColE3 gene under control of the araBAD promoter (ColE3
cassette), a malaria gene under control of the λ promoter (a tem-
perature sensitive promoter), the gentamicin resistance marker,
and the pUC origin of replication and was used as the template
for constructing the pλColE3 plasmid. The ColE3 cassette was
removed by digesting the plasmid with PmeI and SfiI. After gel
purification the vector backbone was self ligated and transformed
into E. coli and plated onto gentamicin plates. DNA plasmid purifi-
cation was performed. The malaria gene was removed by digesting
with NdeI and Not I and the backbone vector was gel purifying.
The ColE3 gene was amplified by PCR using primers that incorpo-
rated NdeI and Not I recognition sites. The amplicon was digested
and then ligated behind the λ promoter, in place of the malaria
gene. The newly constructed “GV200” plasmid was transformed
into E. coli. Sequence confirmation was performed at Genewiz
Inc (South Plainfield, NJ). Expression of the ColE3 gene was also
confirmed by expression profile.
CO-EXPRESSION OF MALARIA TARGET AND INACTIVATION GENES ON
SAME PLASMID FOR SHIGELLA EXPRESSION
A single plasmid was created which contained either of the malaria
antigens as well as the GeMI-Vax inactivation gene, ColE3. The
malaria antigens were controlled by the IPTG inducible pTac
promoter as described above. The ColE3 inactivation gene was
controlled by the lambda promoter, also described above. The
malaria antigen cassette, consisting of the lac repressor, the pTac
promoter, the malaria antigen, and the terminator, was amplified
by PCR using primers which contained restriction enzyme tails.
Once amplification was confirmed by agarose gel electrophore-
sis, restriction enzyme digestion was performed. The cassette was
then ligated into the GV200 vector, which contained the GeMI-Vax
inactivation gene ColE3 under the control of the lambda promoter,
which was then linearized with the same restriction enzymes. Each
of the malaria target antigens was then subcloned into the GV200
vector described above resulting in the double target GV200-
p2xkPfCelTOS and GV200-pHS64PfCSP plasmids, respectively.
Positive clones were obtained and the inserted sequences were ver-
ified by DNA sequencing. Cell inactivation for these constructs
was achieved by a temperature shift from 30 to 40°C resulting in
the denaturation of the c1857 repressor and induction of expres-
sion of the inactivation gene. Upon sequence confirmation the
plasmids were transformed into Shigella and antigen expression
and inactivation studies were performed.
PREPARATION OF S. FLEXNERI 15G-GeMI-VAX CELLS
S. flexneri 15G is an asd mutant strain derived from the parent
2457T strain that is non-replicating in LB medium in the absence
of added diaminopimelic acid (DAP) or within eukaryotic cells
that lack an endogenous source of DAP. Bacteria cells that are asd
mutants have an obligate requirement for DAP, an essential con-
stituent of the cell wall. APF Luria Broth (Athena ES, Baltimore,
MD, USA) supplemented with 2% glucose, 20µg/mL gentamicin,
100µg/mL DAP, was inoculated with 0.15 OD595 of stationary
phase culture S. flexneri 2a 15G. The cultures were grown at 30°C
with shaking at 250 RPM to an OD595 of 0.3 and induced with
1 mM of IPTG. One hour following IPTG induction, an addi-
tional 20µg/mL of gentamicin was added and the temperature
was raised to 40°C for an additional 90 min to induce ColE3 induc-
tion and cell inactivation. 100µg/mL of streptomycin was added
after the 90 min incubation and the cells continued to incubate
for an additional 2.5 h. Cells were collected by centrifugation at
4,000 rpm for 20 min at 4°C. Pellets were resuspended in cold, ster-
ile 1 x PBS (Quality Biological, Gaithersburg, MD, USA). This step
was repeated several times. After a fourth centrifugation, the pel-
let was resuspended in 1×PBS with 100µg/mL of streptomycin
and incubated with gentle rocking at 4°C overnight. Streptomycin
was removed by washing the cell pellet with 1×PBS with at least
four exchanges. Antigen expression was monitored by whole-cell
extraction, SDS-PAGE, and Western blot.
WASHING AND LYOPHILIZATION
Shigella GeMI-Vax cell pellets were washed extensively by the
process of sequential centrifugation and resuspension with four
exchanges of sterile 1×PBS to remove any residual antibiotics. All
subsequent steps are identical to those described above.
IMMUNIZATIONS
Mice used for immunizations were either 6- to 8-week-old
BALB/c-J or C57BL6 (Jackson Laboratories, Bar Harbor, ME,
USA) female mice (n= 10 for challenges and n= 5 for cellu-
lar assays). For all PbCSP and PbCelTOS based immunization,
BALB/c were immunized three times in the scruff of the neck
at 3 week intervals subcutaneously (sc) with either 200µL of
1.7× 109 GeMI-Vax cells or 1µg rPbCSP-tr/ISA 720 (Seppic,
Inc.). For PfCelTOS-based immunizations, BALB/C were immu-
nized three times at 3 week intervals in the scruff of the neck
subcutaneously (sc) with either 1.7× 109 GeMI-Vax cells deliv-
ered in two 100µL aliquots or with 10µg rPfCelTOS/ISA 720
(Seppic, Inc.). All recombinant proteins used had endotoxin lev-
els below the limits of detection (Pyrochrome LAL Kit, Cape Cod
Associates, MA, USA). For PfCSP based immunizations, C57BL6
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mice were immunized four times with 1.7× 109 GeMI-Vax cells
delivered in two 100µL aliquots in the scruff of the neck. Sera were
collected one day prior to each immunization and four weeks after
the last immunization, prior to challenge with either live wild-type
P. berghei sporozoites or live P. berghei P. falciparum CSP transgenic
sporozoites (46).
CHALLENGE
Thirty days after the final immunization, mice were challenged
with either wild-type Plasmodium berghei sporozoites dissected
from infected mosquito salivary glands (4,000 sporozoites for
BALB/c) by subcutaneous inoculation (into the inguinal region)
(47) or (5,000 Pb-PfCSP-transgenic sporozoites for C57BL6)
by intravenous inoculation. Infection was determined by the
presence of blood stage parasites in Giemsa-stained thin blood
smears on days 6, 8, 10, and 14 after challenge. Mice that were
aparasitemic on day 14 were scored as protected (i.e., sterile
protection).
ELISA
The ELISA was performed as previously described (45, 48). Briefly,
96-well plates (Immunolon 2 HB, Thermo Milford, MA, USA)
were coated by overnight incubation with either 50µL of rPbCSP-
tr at 0.05µg or 100µL PfCelTOS and PfCSP at 0.025 and 0.035µg
per well, respectively, in 1×PBS at 4°C. Sera were serially diluted
in blocking buffer and incubated at 37°C for 2 h. Antibody con-
centration was determined by establishing a standard curve (run
with each assay) with purified mouse IgG. For each serum, we
determined a concentration that was within the linear portion
of the reaction curve and used this dilution to extrapolate the
actual antibody concentration in the assay wells. Antibody avidity
measurements were done using the chaotropic agent sodium isoth-
iocyanate (NaSCN) as previously described (48). Briefly, antigen-
specific interactions were disrupted by the addition of varying
amounts of the chaotropic agent NaSCN. Results are reported as
the effective concentration of NaSCN required to release 50% of
antisera (ED50) and are used to evaluate antibody avidities for the
different vaccination groups.
IMMUNOFLUORESENCE ASSAY
Immunofluoresence assay (IFA) were performed as previously
described using salivary gland P. berghei or P. falciparum sporo-
zoites (45).
ELISpot ASSAYS
Cells were stimulated with various concentrations of recombi-
nant protein or 1µg/mL P. berghei CSP peptides CS57-70 (49),
CS58-65 (50), CS260-279 (51), and CS252-260 (52). IFN-γ or IL-
4 specific ELISpot assays (R&D Systems, Minneapolis, MN, USA)
were performed as previously described (45).
WESTERN BLOT ANALYSIS
Protein expression was determined by separating whole-cell
extracts of GeMI-Vax cells (OD600= 0.3) on 4–20% Tris-Glycine
SDS-PAGE. Proteins were transferred to 0.2µm nitrocellulose
membranes (Invitrogen) and blocked with 1×PBS pH 7.4, 0.1%
Tween 20. Blots were probed with PbCSP-specific mAb 4B10 (gen-
erously provided by Dr. Robert Wirtz, CDC), or PfCSP-specific
mAbs (clones WR3 and WR7, WRAIR, Malaria Vaccine Branch) or
PfCelTOS-specific mAbs (clones 3D11.E2, 3C3.C2) or Ag-specific
polyclonal antibodies. Membranes were washed after 1 h incu-
bation and then incubated with alkaline-phosphatase-conjugated
secondary antibodies (Promega, Madison, WI, USA), with either
goat-anti-mouse IgG (1:10,000), goat-anti-human IgG (1:10,000),
or goat-anti-rabbit IgG (1:20,000). Blots were washed and then
developed for 10 min at RT with NBT/BCIP in 0.1 M NaCl, 5 mM
MgCl2, and 0.1 M Tris-HCl pH 9.0. For detection of PbCSP,
membranes were probed with HRP-conjugated mouse mAb 4B10
(1:20,000) for 2 h. Membranes were washed with 1×PBS, 0.05%
Tween 20 prior to applying the Bio-Rad Immun-Star™ West-
ernC™ reagent (Bio-Rad, Laboratories, Hercules, CA, USA). Bio-
Rad’s VersaDoc Imaging system was used to measure the band
intensity after 60 s exposures.
STATISTICAL ANALYSIS
The protective effect of vaccination against P. berghei sporozoite
challenge was evaluated using the Fisher’s exact test comparing dif-
ferences between the GeMI-Vax expressing malaria antigens and
empty cells; adjuvant control groups and recombinant protein vac-
cine groups, respectively. Statistical significance of the serological
data and cellular responses was tested using ANOVA and Stu-
dent T -tests (two-sided), respectively, employing the SigmaPlot
v12 (Systat Software, Inc., San Jose, CA, USA). Data not meeting
normality testing was subsequently tested using Kruskal–Wallace
One-way analysis of variance on ranks.
RESULTS
E. COLI GENE-MEDIATED-INACTIVATION VACCINE EXPRESSING
MALARIA ANTIGENS
Gram-negative E. coli were selected as the bacterial vector sys-
tem to evaluate the GeMI-Vax approach for malaria. These studies
were designed to investigate: (1) the relationship between antigen-
specific dosage levels, (2) effect of sub-cellular localization of anti-
gen, (3) the type of immune responses induced, and (4) the efficacy
of the GeMI-Vax vaccine platform in E. coli. Prior to embarking on
immunological studies, bacterial growth, expression, localization,
and inactivation conditions were established.
Malaria target sequences used for co-expression were codon
harmonized for optimal expression and protein folding in the
bacterial host. The approach relies on codon frequency matching
between the antigen-“donor” species (in this case Plasmodium)
and the “recipient” species (in this case E. coli) yielding regulated
co-translational folding (43).
Malaria targets such as Plasmodium CSP are characterized by
a central, highly repetitive region, which contains varying num-
bers of repeat motifs. These repeat motifs have made it technically
difficult to synthesize full-length CSP genes. Thus, for this pur-
pose, a reduced number of central repeats were incorporated into
the PbCSP sequence. Several plasmid constructs were generated to
express PbCSP on the OM, to the PPS or in the cytosol of recombi-
nant bacteria (Figure 1). Fusing pbcsp with the ompa gene resulted
in insertion into the OM while fusing the CSP gene with the MBP
gene yielded expression to the PPS. Removal of the MBP fusion
partner from the latter construct resulted in the expression of
CSP to the cytosol (Cyto). Despite the engineering to truncate the
central repeat region and expression as fusion proteins, expressed
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FIGURE 1 | Diagram of Gram-negative bacterium representing the outer
membrane, periplasmic space, and the cytosol. PbCSP expression is
represented as either a fusion with outer membrane protein OmpA or in the
periplasmic space with MBP Inner membrane (IM). Cartoons of various cell
surface molecules are included but not drawn to scale, for instance pili,
flagella, LPS, and transmembrane proteins.
CS proteins were recognized by PbCSP-repeat specific monoclonal
antibody 4B10 (Figure 2) and by PbCSP-specific polyclonal anti-
bodies induced in mice with recombinant PbCSP/Montanide ISA
720 (data not shown). These results confirm the cellular expres-
sion and immune-recognition of the CS proteins. High levels of
heterologous expression were measured in the OM (Figure 2A)
and the PPS (Figure 2B), while cytosolic expression was only
detectable after IPTG induction and lost after inactivation and
lyophilization (Figure 2C). The cytosolic expression likely resulted
in intracellular proteolysis in the absence of a fusion partner.
Immunostaining of E. coli GeMI-Vax using a PbCSP-specific
mAb verified the localization and distribution of fusion proteins
(Figure 3). Staining of unfixed OM-PbCSP showed a circum-
ferential staining pattern consistent with its surface expression
through fusion with the OM protein (Figure 3A); while surface
staining of the unfixed PPS-PbCSP cells was negative (Figure 3C)
and required permeabilization of the cells to detect the intracellu-
larly expressed PPS-PbCSP (Figure 3D). PPS-PbCSP staining in
the PPS appeared uniform throughout the bacterium. No surface
staining was observed of OM-PbCSP GeMI-Vax probed with an
irrelevant mAb (Figure 3B).
CSP EXPRESSION TO DIFFERENT CELLULAR COMPARTMENTS ON E.
COLI DICTATES IMMUNE RESPONSES
To evaluate the immune potential of bacterial vectors to induce
malaria-specific responses, mice were immunized with E. coli
GeMI-Vax cells. Based on protein expression estimates made from
Western blots, the total antigen doses delivered were 0.5µg/dose
for OM-PbCSP, 0.1µg/dose for the PPS-PbCSP and below detec-
tion limit for the Cyto-PbCSP. The number of cells delivered
was based on experiments performed to determine tolerability
in BALB/c mice, thus the maximum number of cells delivered for
all constructs was 1.7× 109 cells/dose. OM-PbCSP immunized
mice and a reference group (mice immunized with recombinant
1µg PbCSP/Montanide ISA-720) showed the highest titers of
PbCSP-specific antibodies (Figure 4A). However, in all cases, the
OM-PbfCSP induced CSP-specific antibody responses that were
significantly greater than for any other GeMI-Vax group (Kruskal–
Wallace One-way analysis of variance on ranks, p< 0.001). PPS-
and Cyto-PbCSP immunizations induced responses that could
not be boosted and were not distinguishable from background,
“empty” GeMI-Vax cells. Antibodies to E. coli were measured
against an E. coli lysate by ELISA and did not vary by GeMI-Vax
groups (Figure 4B). For GeMI-Vax groups, only the third immu-
nization with OM-PbCSP boosted PbCSP-specific responses,how-
ever they were not statistically different compared with responses
induce by the recombinant protein PbCSP/ISA 720 on Day 56,
just prior to sporozoite challenge (ANOVA, p= 0.06). All GeMI-
Vax groups had similar levels of anti-E. coli vector background
responses by time of challenge. To characterize whether the
PbCSP-specific antibodies recognize native antigen, IFAs with P.
berghei sporozoites were performed (Figure 5). Only sera from
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32
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32
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FIGURE 2 | Western blot expression profiles of GeMI-Vax PbCSP from
different sub-cellular localizations. (A) Targeting PbCSP to the outer
membrane, OM-PbCSP. Lanes: 5 ng rPbCSP; un-induced cells (T0), 1 h post
IPTG induction (T1h), post ColE3 inactivation, post lyophilization; (B) Targeting
PbCSP to the periplasmic space, PPS-PbCSP. Lanes: un-induced cells (T0), 1 h
post IPTG induction (T1h), post ColE3 inactivation, post lyophilization; 1µg
rPbCSP. (C) Expression of PbCSP to the cytoplasmic space. Lanes:
un-induced cells (T0), 1 h post IPTG induction (T1h), post ColE3 inactivation,
post lyophilization, 1µg rPbCSP. Arrow points to rPbCSP which migrates at
∼32 kDa. Final lyophilized product loaded at 1.2×107 cells per lane.
A B
C
D
FIGURE 3 | PbCSP-specific antibodies react with recombinant
expressing PbCSP GeMI-Vax bacteria. Bacteria expressing
PbCSP in the outer membrane (A,B) or periplasmic space (C,D)
were stained with the PbCSP-specific mAb 4B10 (A,C,D) or
control mAb (2C6.7 MSP119 specific mAb) (B). Bacteria were
stained for surface expression (A,C) or after permeabilization for
intracellular expression (D). Representative images were taken at
1,000× magnification.
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FIGURE 4 | OM-PbCSP GeMI-Vax bacteria induce strong humoral
immune responses. Sera from mice immunized with either OM-PbCSP,
PPS-PbCSP, Cyto-PbCSP, or recombinant PbCSP adjuvanted with
Montanide ISA-720 were collected two days prior to each immunization
and tested for reactivity against rPbCSP (A) or on E. coli lysates (B).
Data are expressed as geometric mean in µg/mL of antigen-specific IgG
(n=15 mice/group), and the error bars indicate the 95% confidence
interval. NS denotes not statistically significant. Asterisk indicates
statistical significance, **p<0.001; Kruskal–Wallace One-Way Analysis
of Variance on Ranks.
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FIGURE 5 | OM-PbCSP-GeMI-Vax (A) and PbCSP/ISA-720 (B) induce
antibodies that react with P. berghei sporozoites by indirect
immunofluorescence. The reactivity was specific as sera from mice
immunized with empty GeMI-Vax did not react with sporozoites (C).
Representative images were taken at 1,000×magnification, staining at
1:10,000 dilutions.
mice immunized with either OM-PbCSP or the recombinant
PbCSP had IFA-reactive antibodies. The mean endpoint titer of
the OM-PbCSP was 1:64,000, while the mean endpoint titer of the
recombinant PbCSP was 1:125,000. Sera from other GeMI-Vax
groups failed to react with sporozoites above the background level
of the empty GeMI-Vax group. Lack of reactivity to sporozoites
could be due to: (a) GeMI-Vax expressing the PbCSP-induced epi-
tope specificities not present or accessible in the native CSP on
sporozoites or (b) the concentration or avidity of the antibodies
was too low to detect binding or (c) the inability of the intracel-
lular PbCSP delivery to significantly mount humoral responses at
the doses of antigen delivered. Avidity measurements were per-
formed using the chaotropic agent NaSCN in ELISAs to compare
the OM-PbCSP and soluble protein PbCSP/ISA 720 responses.
OM-PbCSP-induced antibody responses with enhanced avidity
compared to the conventional antigen/adjuvant approach (ED50
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NaSCN (mol/L) for OM-PbCSP and PbCSP/ISA 720, 2.0 versus
1.0, respectively).
To determine the effect of antigen localization on the induction
of cellular responses, spleens from immunized mice were stimu-
lated ex vivo with recombinant PbCSP as well as PbCSP-derived
peptides representing immunodominant CD4 or CD8 epitopes.
T cell responses were measured by the number of IFN-γ and IL-
4 producing cells responding to antigen stimulation in ELISpot
assays (Figures 6A,B). The responses to the recombinant pro-
tein and peptides for the rPbCSP/ISA 720 group were significantly
higher than for any GeMI-Vax group (p< 0.03, p< 0.001, respec-
tively, Student’s T -test). Interestingly, the magnitude of the T cell
response did not parallel the magnitude of the antibody response
since both the PPS-PbCSP and Cyto-PbCSP groups had similar
numbers of IFN-γ spot-forming cells (SFC) as the OM-PbCSP
group. The IFN-γ responses measured in the GeMI-Vax groups
were significantly higher than those observed in the empty GeMI-
Vax (control group) demonstrating antigen-specificity (p< 0.001,
ANOVA). In contrast to the antibody responses, the differences
in antigen localization and doses delivered by the different bac-
terial vectors did not appear to affect the overall magnitude of
the cellular responses. Neither the GeMI-Vax groups nor the
PbCSP/ISA 720 group mounted a significant Th2 type cellu-
lar response, as indicated by the overall lack of IL-4 production
(Figure 6B).
To further explore the role of cellular localization and the mod-
ulation of immune responses, similar constructs to those describe
for PbCSP were generated for expressing the PbCelTOS antigen
(i.e., OM-PbCelTOS and PPS-PbCelTOS). CelTOS is a secreted,
micronemal protein expressed from salivary gland sporozoites
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FIGURE 6 | E. coli GeMI-Vax induceTh1 but notTh2 responses. GeMI-Vax
constructs (indicated on the X -axis) were tested for their ability to mount
antigen-specific IFN-γ responses (A,C), and IL-4 responses (B,D) after
antigen-specific stimulation. (A,B) Splenocytes stimulated ex vivo with either
recombinant PbCSP (10µg/mL) or PbCSP-derived peptides (peptide
mix=pool of all four peptides, peptides CS 57-70 and CS 242-279 represent
I-Ad restricted CD4+ epitopes, peptides CS 58-65 and CS 252-60 represents
H2Kd-restricted CD8+ epitopes). GST=negative control. (C,D) Splenocytes
stimulated ex vivo with either recombinant PbCelTOS or GST protein
(30µg/mL). Data are expressed as the mean and standard error of the mean
(SEM) number of spot-forming cells (SFC) from n=5 mice/group. Asterisk
indicates statistical significance (Students T -test): *p<0.05, **p<0.001.
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through early liver cell infection stages. Preclinical experiments
utilizing recombinant protein revealed that CelTOS-based immu-
nity is highly conserved and results in protection against sporozoite
challenge in a homologous (44) and a heterologous (45) challenge
model and that the protection is dependent on both cellular and
humoral immunity (44). The observed cross-species protection
is a unique feature of the CelTOS antigen and allows for evalu-
ation of P. falciparum CelTOS in the P. berghei murine model.
Unlike for OM-PbCSP, mice immunized with OM-PbCelTOS
did not induce significant levels of antibodies above background
(data not shown); however, a significant cellular response that
was skewed toward Th1 was evident (Figures 6C,D). In this case,
localization of CelTOS to the surface or the PPS yielded IFN-γ
responses that were significantly different (p< 0.001,T -test). Only
the OM-PbCelTOS construct induced IL-4 responses that were sig-
nificantly different from the empty GeMI-Vax control (p< 0.01,
T -test).
To evaluate the in vivo efficacy, BALB/c mice were chal-
lenged by injecting 4,000 salivary gland P. berghei sporozoites
subcutaneously (SQ). We have previously shown that the SQ
route better mimics the natural infection route than does the
intravenous route (IV) by engaging humoral immune mecha-
nisms (47). Mice that remained aparasitemic on day 14 after
challenge were considered sterilely protected (Table 2). Ster-
ile protection was observed in mice immunized with the OM-
PbCSP, while PPS- and Cyto-PbCSP were only able to induce
partial protection. Some mice were re-challenged 10 weeks after
the initial challenge to determine (1) whether protection was
long-lasting, and (2) whether the exposure to the parasites dur-
ing the first challenge edited the immune response (48). Only
mice immunized with OM-PbCSP achieved complete protec-
tion (7/7 mice) upon re-challenge (Table 2). Although low
numbers of animals were re-challenged, these results suggest
the GeMI-Vax platform is capable of inducing long-lasting
immunity.
TRANSLATION TO CLINICALLY RELEVANT SHIGELLA FLEXNERI
15G-GeMI-VAX EXPRESSING MALARIAL ANTIGENS
After the initial success using E. coli, the GeMI-Vax platform was
adapted to an asd mutant of S. flexneri 2a (15G strain). The
rationale for switching to Shigella was based on safety concerns
related to immunization with a commensal E. coli present in the
host gut. Attenuated derivatives of the S. flexneri 2a have previ-
ously been tested as oral vaccines to prevent shigellosis (30, 53,
54) and used in animal studies as potential multivalent mucosal
vaccine candidates for delivery of bacterial antigens and eukary-
otic genes (55). An asd mutant of Shigella is unable to grow in
the absence of DAP, an essential peptidoglycan component of the
bacterial cell wall. Since mammalian cells lack DAP, Shigella asd
mutants can readily invade epithelial cells but are unable to repli-
cate thus rendering them highly attenuated. Facile transition from
E. coli to Shigella was achieved due to their genetic similarities
thus allowing identical approaches for establishing the GeMI-Vax
Shigella concept. The malaria targets were derived from the lethal
Plasmodium spp., P. falciparum, and were engineered for cellu-
lar localization as described for the P. berghei CSP and CelTOS.
Based on results from E. coli GeMI-Vax, the PfCSP was targeted
to the OM while the CelTOS antigen was targeted to the PPS of
Shigella. Because of its native surface localization, the objective for
the OM-PfCSP was to achieve strong antibody responses while
the intracellular PPS-PfCelTOS was intended to induce primarily
T cell responses. Since in these experiments Shigella GeMI-Vax
was delivered by parenteral routes the immune responses were
focused on the malaria antigens and not the shigella delivery
vehicle.
Expression levels of the S. flexneri 15G encoding either OM-
PfCSP or PPS-PfCelTOS were confirmed by Western blotting with
antigen-specific mAbs (Figure 7). OM-PfCSP was detected by
polyclonal mouse antisera as well as mAbs specific for the C-
terminus (clone WR7) or the central repeat, NANP region (clone
WR3) (Figure 7A) of the P. falciparum CSP. Both the C-terminal
Table 2 | GeMI-Vax induce long-lasting protective immunity that varies by sub-cellular localization.
Immunization group First challenge Re-challenged
Protected/total Efficacy (%)a p-Valueb Protected/total Efficacy (%)a p-Valueb
OM-PbCSPd 27/35 68 <0.0001 7/7 100 0.0002
PPS-PbCSPd 17/25 55 0.02 3/6 50 0.06
Cyto-PbCSP 4/10 14 0.5 3/4 75 0.02
rPbCSP/ISA 720d 24/30 76 <0.0001 7/8 88 0.0007
ISA 720d 5/29 – – ND – –
Empty GeMI-Vaxd 10/34 – – ND – –
Naïvec ND – – 0/8 – –
OM-PbCelTOS 5/10 29 0.144 ND – –
PPS-PbCelTOS 7/10 58 0.027 ND – –
aEfficacy (%)= {1− [(Expinfected/Exptotal)/(Continfected/conttotal)]}×100.
bSignificance was determined by using Fisher’s Exact Test.
cNaïve mice served as infectivity controls for the re-challenge experiment.
dProtection results from three independent experiments. Only mice from the first protection study were re-challenged.
ND= not done.
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FIGURE 7 | Analysis of expression levels of malarial antigens from the
different sub-cellular compartments on Shigella GeMI-Vax. Lysates from
GeMI-Vax expressing OM-Pf CSP (A) or PPS-Pf CelTOS (B) were probed with
antigen-specific mAbs and polyclonal Abs: clone WR7=Pf CSP C-terminus
specific mAb; clone WR3=Pf CSP repeat region-specific mAb,
polyclonal= serum pooled from mice immunized with recombinant Pf CSP;
3D11.E2=Pf CelTOS-specific, conformation-dependent mAb;
3C3.C2=Pf CelTOS-specific, conformation-independent mAb;
polyclonal= serum pool from rabbits immunized with recombinant
Pf CelTOS/ISA 720. Arrows indicate fusion protein in molecular mass. G is
GeMI-Vax lysate; P is recombinant protein. Molecular weight of the rPf CSP is
34 kDa and the rPf CelTOS is 19.1 kDa.
and the repeat region-specific mAbs recognized the OM-PbCSP
fusion protein (68.5 kDa) and the recombinant full-length protein,
rPfCSP (∼32 kDa). For immunizations, the amount of OM-PfCSP
delivered was estimated to be 0.05µg (low dose) and 5µg (high
dose) per dose based on immunoreactivities on Western blots.
Expression of PPS-PfCelTOS was confirmed by Western blots
probed with CelTOS specific mAbs and polyclonal antibodies
(Figure 7B). The fusion protein was confirmed to have a size of
∼61 kDa. Fine specificity of the PfCelTOS-specific mAbs indi-
cate that anti-PfCelTOS mAb 3C3.C2 binds primarily to linear
C-terminal epitopes while mAb 3D11.E2 binds primarily to the
recombinant PfCelTOS protein indicating specificity for a con-
formational epitope. The lack of immunoreactivity by the mAb
3C3.C2 to the PPS-PfCelTOS protein suggests that the binding epi-
tope for this mAb may not be accessible due to folding constraints.
Both mAbs 3C3.C2 and 3D11.E2 and the polyclonal immune sera
recognized the reference protein, rPfCelTOS (19 kDa). Based on
Western blot probing the amount of PPS-PfCelTOS delivered dur-
ing immunizations was estimated to be ∼0.01µg (low dose) and
1µg (high dose) per dose.
INDUCTION OF PfCelTOS OR PfCSP-SPECIFIC ANTIBODY RESPONSES
BY SHIGELLA GeMI-Vax DEPENDS ON ANTIGEN LOCALIZATION
The immunogenicity of GeMI-Vax expressing PfCelTOS or PfCSP
was evaluated by immunizing mice with a high dose (1µg) or
low dose (0.01µg) of PPS-PfCelTOS or high dose (5µg) or low
dose (0.05µg) of OM-PfCSP. The doses were selected based on
the initial experiments performed with E. coli where 1.7× 109
cells/mouse/dose was the highest tolerated dose. The kinetics of
the antibody response in the immunized mice confirmed the ear-
lier observation that targeting the antigen to the OM results in
more robust humoral responses (Figure 8). Due to issues related
to the availability of P. berghei PfCSP-transgenic sporozoites for
challenge it was necessary to include a fourth immunization of the
OM-PfCSP GeMI-Vax. Delivering a higher dose of GeMI-Vax cells
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FIGURE 8 | Kinetics of the humoral immune responses induced by
Shigella GeMI-Vax. Sera from mice immunized with OM-Pf CSP HD (high
dose) and OM-Pf CSP LD (low dose) were collected prior to, 3 weeks after
each immunization and 1 day prior to the challenge and were analyzed using
a quantitative ELISA. Data are expressed as the geometric mean
Pf CSP-specific antibody concentration (µg/mL) and the error bars represent
the 95% confidence interval of n=10 mice/group. Arrows indicate the days
of immunizations, Day-1, 20, 41, and 113, and the bolt indicates time of
challenge. Mice were immunized with either high dose=1.7×109 cells or
low dose=1.7×107 number of cells. At each time point following the
primary immunization, Pf CSP-specific antibody responses for the
OM-Pf CSP HD group were significantly higher than for the OM-Pf CSP LD
group (ANOVA, p<0.05).
yielded statistically significant higher antigen-specific antibody
responses at all time points (ANOVA, p< 0.05). Based on anti-
body kinetics, the fourth immunization did not significantly boost
the response in the group receiving the high dose of OM-PfCSP.
In contrast, the PPS-PfCelTOS groups did not show any signif-
icant antigen-specific antibodies above the background empty
GeMI-Vax control cells (data not shown). IFA-results using P. fal-
ciparum sporozoites paralleled and confirmed the results from
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the ELISA in that immunization with OM-PfCSP led to high
titers of CSP antibodies that are sporozoite-reactive, while the
titers induced by the PPS-PfCelTOS were negligible (data not
shown).
T CELL RESPONSES DIFFERED BY TARGETING TO CELLULAR
COMPONENTS
Immunization with OM-PfCSP induced PfCSP antigen-specific
IFN-γ and IL-4 producing T cells with an apparent bias toward
Th1-type responses compared to stimulations with irrelevant pro-
tein (GST as negative control) (Figure 9A). In contrast to the IFN-
γ responses, the magnitude of the IL-4 responses was dependent
on the immunization dose, however, only splenocytes stimulated
with 30µg/mL PfCSP yielding a significant difference between
the two dosage groups (Student’s t -test; p< 0.05). Immuniza-
tion with the PPS-PfCelTOS induced a relatively more balanced
T cell response that did not significantly change as a function of
the immunization dose, except for the low dose PPS-PfCelTOS
splenocytes stimulated with 3µg/mL of recombinant CelTOS,
which were significantly higher than high dose (Students t -test;
p< 0.05) (Figure 9B). The ability of the PPS-construct to induce
antigen-specific T cells while failing to induce significant antibod-
ies supports the earlier finding that localization to the periplasm
leads to predominantly cellular responses.
SHIGELLA GeMI-Vax CELLS INDUCED PROTECTIVE IMMUNITY
MEDIATED BY PfCelTOS IN THE PERIPLASM
To evaluate the protective efficacy of the PPS-PfCelTOS, mice
were challenged with wild-type P. berghei parasites (45) while
the OM-PfCSP mice were challenged with PfCSP-transgenic P.
berghei parasites (46). A summary of the Shigella GeMI-Vax-
induced protection is shown in Table 3. The level of protec-
tion induced by PPS-PfCelTOS was comparable to previously
reported results using 10µg PfCelTOS/Montanide ISA-720 (45).
The effective antigen dose delivered by Shigella PPS-PfCelTOS was
10-fold lower than for soluble protein/adjuvant. When equivalent
low doses of recombinant protein were delivered as soluble pro-
tein/adjuvant, no protection was observed (45), suggesting that
the PPS-PfCelTOS GeMI-Vax approach is antigen dose sparing.
Although the high dose of S. flexneri GeMI-Vax OM-PfCSP also
induced a dose-dependent, antigen-specific antibody response, no
significant protection was observed in contrast to the observations
with the OM-PbCSP in E. coli.
DISCUSSION
New and improved methods for the simultaneous presentation
of pathogenic antigens and immune stimulation are needed for
the development of efficacious vaccines. Platforms that present
antigen to the host immune system in a particulate manner can
mimic the structure of a natural pathogen leading to improved
immunogenicity. GeMI-Vax are intact, Gram-negative bacteria,
that are inactivated through genetic means and provide a deliv-
ery platform for presenting xenogeneic expressed target antigens
with intrinsic danger signals to the host immune system. Although
immunostimulatory, and from a safety standpoint, the endotoxin
constituent of Gram-negative OMs does not limit their use as
vaccine vectors primarily due to their minimal toxicity when
presented as cell-associated lipopolysaccharides compared to the
free-soluble forms (56).
In this study, GeMI-Vax served to evaluate the induction
of antigen-specific humoral and cellular immune responses by
expressing malaria proteins to different sub-cellular localizations.
Localization of the PbCSP in E. coli GeMI-Vax to different cel-
lular compartments induced distinct immune responses. PbCSP
fused to the OM induced both humoral and Th1 cellular responses
that induced sterile protection against homologous sporozoite
challenge. Immunostaining of OM-PbCSP GeMI-Vax verified the
surface localization and revealed a punctate and circumferential
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FIGURE 9 | Shigella GeMI-Vax-induced a balancedT cell response that is
dose-independent. Splenocytes from mice immunized with either
OM-Pf CSP (A) or PPS-Pf CelTOS (B) were stimulated ex vivo with the
respective recombinant protein (either rPf CSP or rPf CelTOS) or GST (negative
control). Data are expressed as the mean and standard error from the mean
(SEM) number of spot-forming cells (SFC) from n=5 mice/group. Mice were
immunized with either High dose=1.7×109 or Low dose=1.7× 107 number
of cells. Asterisk indicates statistical significance (Students T -test; *p<0.05).
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Table 3 | Immunization with high dose PPS-PfCelTOS protects mice against challenge with wild-type P. berghei sporozoites.
Immunization group Parasite challenge Dosea, #Cells Protected/total Efficacy (%)b p-Valuec
OM-Pf CSP Pf CSP-transgenic (IV route) High, 1.7×109 2/9 13.5 0.46
Low, 1.7×107 4/10 33 0.15
Empty GeMI-Vax High, 1.7×109 1/10 – –
Saline – 0/10 – –
PPS-Pf CelTOS P. berghei WT (SC route) High, 1.7×109 6/10 55 0.04
Low, 1.7×107 4/10 32.5 0.18
Empty GeMI-Vax High, 1.7×109 1/9 – –
aHigh dose= 1.7×109 cells; low dose=1.7×107 cells.
bEfficacy (%)= {1− [(Expinfected/Exptotal)/(Continfected/Conttotal)]}×100.
cSignificance was determined by using Fisher’s Exact test.
staining pattern that mimicked the authentic conformational dis-
play of CSP on sporozoites. Interestingly, none of the intracellular
PbCSP localizations whether to the PPS or to the cytosol, induced
high levels of PbCSP-specific antibodies. However, sub-cellular
localizations of PbCSP led to the induction of IFN-γ responses by
both CD4 and CD8 T cells, recognizing peptide epitopes through-
out PbCSP (Figure 6). In contrast to PbCSP, OM localization of
the PbCelTOS did not lead to pronounced levels of antibody.
These results point to both cellular localization and the nature
of the target antigen in influencing the induced immunity. Thus
the key immunological findings are (1) protection was high-
est in the groups that mounted significant antibody responses,
(2) PbCSP-antigen delivered by GeMI-Vax from different sub-
cellular localizations does not influence the magnitude of the
IFN-γ responses; and (3) none of the PbCSP-GeMI-Vax con-
structs induced significant PbCSP-specific IL-4 responses. These
findings are consistent with other studies where PbCSP-specific
antibodies were shown to play an important role in protection
against a homologous sporozoite challenge (48). In the current
study, the longevity of the protective response and its robustness
against parasitic editing was measured by re-challenging the pro-
tected mice 10 weeks after the first challenge (Table 2). Only the
OM-PbCSP immunized mice which notably had the highest anti-
body response and a concomitant Th1-type cellular response were
completely protected. Currently, it is unclear whether the surface
presentation on bacteria led to extended persistence of the anti-
gen on follicular dendritic cells as described for other targeted
vaccines (48). Another explanation for the sustained protection
could be an increase in the precursor frequency of high-avidity
B cells induced by lower antigen doses in the context of a potent
activator of the innate immune system, a hypothesis supported by
the finding that immune sera induced by OM-PbCSP GeMI-Vax
had higher avidities than did the soluble protein/adjuvant. Thus
presentation of PbCSP on the bacterial surface likely resembled
the natural surface display on sporozoites and the adjuvanticity of
the bacterium led to robust humoral responses despite the lower
antigen dose. Concomitantly, surface display of PPS-PbCelTOS
did not generate significant levels of antibodies and the protec-
tion seen was primarily due to a potent Th1-type IFN-γ T cell
response. The present study emphasizes that the nature of the
antigen; and both the quantity and quality of vaccine-induced
immune responses, have a role in the potency of this vaccine
platform.
The efficacy of Shigella GeMI-Vax OM-PfCSP differed from
the results obtained in E. coli since the OM-PfCSP did not lead to
significant protection against sporozoite challenge. One difference
between the two experiments was the challenge route: the PbCSP
E. coli GeMI-Vax construct were evaluated using the subcuta-
neous injection with wild-type P. berghei sporozoites which more
closely mimics the natural challenge route (mosquito bite) (47).
In contrast, the PfCSP Shigella GeMI-Vax constructs were eval-
uated using intravenous injection of PfCSP-transgenic P. berghei
sporozoites. By injecting sporozoites directly IV, effector antibod-
ies may have had little chance to contribute to protection (57).
In this case, the partial protection may be attributed solely to the
cellular responses induced by this vaccine. While the periplasmic
location of the PbCSP did not induce statistically significant pro-
tective immunity, the opposite was seen with PfCelTOS localized
to the PPS. These findings further confirm that the protection is
not solely a function of the sub-cellular localization but that (a)
the nature of the antigen and (b) the antigen-specific dosage levels
may contribute to protection.
These results reveal that GeMI-Vax expressing the two major
pre-erythrocytic targets, CSP or CelTOS, can elicit protective effi-
cacy against homologous sporozoite challenge in murine models.
In comparison with other vaccine technologies, the GeMI-Vax
platform has several advantages: (a) ease and low cost of manufac-
turing; (b) highly stable final lyophilized product well suited for
cold chain-free transport to remote field sites; (c) self-adjuvanting;
(d) induces high-avidity antibodies known to be more efficacious
in mediating protection; (e) triggers distinct immune responses
by the choice of cellular localization of the target antigen; (f) inte-
gration with Gram-negative human pathogens such as Shigella
GeMI-Vax holds the possibility for a dual-use vaccine to mediate
protection against shigellosis and xenogeneic antigen(s) expressed
by the bacteria. Finally, based on practical issues, GeMI-Vax may
be suitable for use in the early immunological characterization of
novel target antigens identified from high throughput antigen dis-
covery projects. Using relatively standard molecular engineering,
novel targets can be expressed and delivered to assess their immune
potential in murine models without time consuming protein
purification and process development. GeMI-Vax is also suitable
www.frontiersin.org July 2013 | Volume 4 | Article 176 | 13
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for high density display of target antigens and can be easily inte-
grated into a multi-epitope, multi-stage malaria vaccine system.
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